A SPAC III Acquisition Corp.

What they do

Incorporated on September 3, 2021 as a British Virgin Islands business company, ASPAC III has no operations and exists to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It consummated its IPO on November 12, 2024 and, as of December 31, 2025, had not commenced any operations; all activity since inception has been organizational, IPO preparation and searching for and negotiating with potential targets. The company states it will not generate operating revenues until after completing its initial business combination.

Revenue drivers

• No operating revenue — The company has no products or customers and reported no operating revenue; pre-combination income comes from interest earned on the $60,000,000 held in the trust account, which is the only source of income described in the filings.
• IPO and private placement proceeds — Proceeds of $55,000,000 from 5,500,000 IPO units at $10.00, $5,000,000 from 500,000 over-allotment units, and $2,850,000 from 285,000 private placement units sold to the Sponsor funded the trust account.
• Post-combination target business — Any future revenue would come from the business it acquires; no target, industry or transaction has been identified in the filings provided.

Recent performance

Annual net income went from a $2,650 loss in 2023 to a $226,383 loss in 2024 and then to $1.3 million of net income in 2025, reflecting trust interest rather than operations. Operating cash flow remained negative at $473,887 in 2024 and $451,319 in 2025. At June 30, 2026, total assets were $3.8 million against total liabilities of $560,564 and shareholder equity of $237,744, with $633,724 of cash and equivalents. Shareholders' equity fell below Nasdaq's $2,500,000 continued-listing minimum for the quarter ended March 31, 2026, triggering a May 20, 2026 Nasdaq deficiency letter. On January 16, 2026, the Sponsor exchanged 1,499,900 Class B ordinary shares for 1,499,900 Class A ordinary shares.

Strategy

Management's stated purpose is to identify and complete an initial business combination, funded with IPO proceeds, the private placement proceeds and securities sold in connection with the transaction. The company submitted a compliance plan to Nasdaq on July 1, 2026 and requested an extension until November 16, 2026 to regain the minimum stockholders' equity requirement. The plan proposed that the remedy occur in connection with the proposed business combination, which the filings reference but do not yet identify or confirm. The company says it expects to continue incurring significant costs in pursuit of an acquisition and cautions it cannot assure the plans will succeed.

Risks

• Nasdaq listing deficiency — Stockholders' equity at March 31, 2026 was below the $2,500,000 minimum required by Nasdaq Listing Rule 5550(b)(1), prompting a May 20, 2026 deficiency letter and a compliance plan requesting an extension to November 16, 2026.
• No identified target or assurance of completion — The filings state the company has not commenced operations, has no operating revenue and cannot assure that plans to complete a business combination will be successful.
• Trust deadline and redemption risk — The $60,000,000 in the trust account may be released only for taxes, shareholder-approved amendments, or redemption of all public shares if no business combination is completed within the combination period.
• Negative operating cash flow and small equity base — Operating cash flow was negative $473,887 in 2024 and negative $451,319 in 2025, and equity was $237,744 at June 30, 2026 against total liabilities of $560,564.

Outlook

Management states it expects to continue incurring significant costs while pursuing an acquisition and that it cannot assure the plans will be successful. The Nasdaq compliance plan contemplates remedying the equity deficiency in connection with the proposed business combination, with a requested extension to November 16, 2026. No target, industry or transaction terms are disclosed in the provided excerpts.